Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1443
- Development stage
- Phase 1
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1443 is an investigational mRNA-based vaccine developed by Moderna for the prevention of cytomegalovirus (CMV) infections. It encodes a phosphorylation mutant of the CMV pp65 protein, designed to stimulate an immune response against CMV. The vaccine uses nucleoside-modified messenger RNA encapsulated in lipid nanoparticles for delivery. Its mechanism of action is immunostimulation, aiming to elicit both humoral and cellular immunity against CMV by presenting the pp65 antigen to the immune system[1][3][4]. mRNA-1443 has been studied as part of combination regimens with other CMV antigens (such as in combination with mRNA-1647), but no recent clinical development has been reported beyond phase 1 trials[1][5].
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on mRNA-1443.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1443.